Drug Interaction Between Colchicine and Calcineurin Inhibitors in Renal Graft Recipients (COLCHINCAL)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01160276 |
Recruitment Status :
Completed
First Posted : July 12, 2010
Last Update Posted : April 11, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Ciclosporin inhibits P-glycoprotein should increase colchicine bioavailability whereas tacrolimus should not influence colchicine disposition.
This is a prospective, controlled, open labeled study performed in renal graft recipients comparing colchicine single dose (1mg) pharmacokinetics in 14 patients treated with tacrolimus and 14 patients treated with cyclosporin.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Renal Replacement Therapies | Drug: cyclosporine+colchicine Drug: tacrolimus | Phase 1 |
- Renal transplantation >= one year
- eGFR (MDRD) > 30ml/min
- hemoglobin >= 11g/dl
- treatment with tacrolimus or cyclosporine
- no previous muscular disease
- no drugs interfering with P-glycoprotein or CYP3A activity or expression outcomes
- colchicine AUC, Cmax, T1/2
- ABCB1C3435T, CYP3A5 and SLCO1B1 genotypes
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 17 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open Non Randomized Comparative Study Exploring Drug Interaction Between Colchicine and Calcineurin Inhibitors in 2 Groups (Ciclosporin Group and Tacrolimus Group) of Renal Graft Recipients |
Study Start Date : | May 2010 |
Actual Primary Completion Date : | January 2012 |
Actual Study Completion Date : | January 2012 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Cyclosporine
The first group is composed of 14 renal graft recipients under cyclosporine
|
Drug: cyclosporine+colchicine
the 14 patients of the 1st group are under cyclosporine and One pill of colchimax 1mg will be taken by all the patients at Day 3.
Other Names:
|
Active Comparator: Tacrolimus
The second group is composed of 14 renal graft recipients under tacrolimus
|
Drug: tacrolimus
the 14 patients of the second group are under tacrolimus and One pill of colchimax 1mg will be taken by all the patients at Day 3.
Other Names:
|
- Area under the curve of plasma concentration of colchicine over time 0-∞ [ Time Frame: 4 weeks ]
- Half-life of colchicine (T1/2). [ Time Frame: 4 weeks ]
- AUC0-3h colchicine to focus the analysis on the absorption phase (argument in favor of an interaction-dependent P-gp) [ Time Frame: 4 weeks ]
- Cmax observed colchicine. [ Time Frame: 4 weeks ]
- Residual tacrolimus or cyclosporine concentrations [ Time Frame: 4 weeks ]
- ABCB1 genotype at position 3435 (rs 1045642) or 3435 cc, 3435TT, heterozygotes could not be included in the tacrolimus group. [ Time Frame: 4 weeks ]
- ABCB1 Haplotypes composed of 3 SNPs: C3435T, G2677T / A and C1236T. [ Time Frame: 4 weeks ]
- CYP3A5 Genotype: search for the allele * 1 (rs 776746): 3 possible genotypes CYP3A5 * 3 / * 3 - CYP3A5 * 3 / * 1 - CYP3A5 * 1 / * 1. [ Time Frame: 4 weeks ]
- GFR calculated by MDRD formula. [ Time Frame: 4 weeks ]
- BMI [ Time Frame: 4 weeks ]
- Drug related (azathioprine, mycophenolic acid, diuretics, ACE inhibitors, ARAII) [ Time Frame: 4 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with renal graft since at least 1 year
- Patients treated with ciclosporin or tacrolimus
- Are at least 18 years old.
- Glomerular filtration rate above 30 ml / min calculated using the MDRD formula
- Among the 14 patients receiving ciclosporin:
- The genotype is not a criterion for inclusion
- Among the 14 patients with tacrolimus treatment:
- 7 genotype ABCB1 3435CC, 7 genotype ABCB1 3435TT
- Recent (1 month) residual concentration of tacrolimus between 5-10ng/ml
- Recent (1 month) residual concentration of ciclosporin between 100-200ng/ml
- For women : a negative pregnancy test (serum beta hCG)
- Realization of a medical examination.
- Informed consent and writing form.
Exclusion Criteria:
- Abnormal transaminases (AST and ALT above the ULN Laboratory).
- Underlying Liver Disease (steatosis, cirrhosis, chronic hepatitis, the virus of hepatitis C or B).
- Previous history of muscle disease (drug related especially the statin type).
- Leukopenia (WBC <3000/mm3).
- Hemoglobin <11g/dl.
- Patient treated by erythropoetin (whatever its hemoglobin value).
- Abnormal CPK (greater than the ULN Laboratory).
- Prior intolerance to colchicine.
- Regular intake of the following medications associated with rhabdomyolyses: antipsychotics, cholesterol lowering agents (statins or fibrates), zidovudine, antidepressants (selective inhibitor of serotonin reuptake) and lithium.
- Patient (e) can not refrain from consuming grapefruit juice.
- Patient (e) taking a tea based on St John's wort.
- Taking drugs inducers of P-gp or CYP3A4 (rifabutin, rifampin, carbamazepine, phenytoin, phenobarbital, efavirenz, nevirapine, protease inhibitors, griseofulvin).
- Taking drugs inhibitors of P-gp or CYP3A4 (quinidine, macrolide antibiotics, azole antifungals, protease inhibitors, amiodarone, diltiazem, verapamil).
- Chronic diarrhea.
- ABCB1 Genotype 3435CT for patients in the tacrolimus group.
- Participation in another concurrent trial.
- Patient (e) exclusion period of another trial.
- Patient (e) having reached the maximum annual amount of compensation provided by law.
- No affiliation to French social security scheme or without CMU.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01160276
France | |
Assistance publique - Hôpitaux de Paris : Bicêtre Hospital | |
Le Kremlin Bicêtre, France, 94275 |
Principal Investigator: | Antoine Jacquet, MD | Nephrology Department of BICETRE Hospital |
Responsible Party: | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT01160276 |
Other Study ID Numbers: |
P081105 |
First Posted: | July 12, 2010 Key Record Dates |
Last Update Posted: | April 11, 2013 |
Last Verified: | April 2013 |
renal graft colchicine drug interaction cyclosporine tacrolimus |
renal transplantation renal transplant ABCB1 CYP3A5 SLCO1B1 |
Cyclosporine Colchicine Tacrolimus Cyclosporins Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Calcineurin Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
Antifungal Agents Anti-Infective Agents Dermatologic Agents Antirheumatic Agents Gout Suppressants Tubulin Modulators Antimitotic Agents Mitosis Modulators Antineoplastic Agents |